Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RASSF1
REST API REST API
Homo sapiens
RASSF1 is differentially expressed in 255 experiments: 103 organism parts: kidney, liver, ... (101 more);, 163 disease states: normal, lung adenocarcinoma, ... (161 more);, 84 cell types 298 cell lines 34 compound treatments and 68 other conditions.
Synonyms RDA32, 123F2, NORE2A, REH3P21
Orthologs rassf1 (Danio rerio)   RASSF1 (Bos taurus)   ENSCING00000001622 (Ciona intestinalis)   Rassf1 (Mus musculus)   Rassf1 (Rattus norvegicus)   rassf1 (Xenopus laevis)   RASSF1 (Canis familiaris)   (Compare orthologs)
InterPro Term SARAH, Ras-assoc, Prot_Kinase_C-like_PE/DAG-bd
Gene Ontology Term spindle pole, protein stabilization, protein binding, cytoplasm, protein N-terminus binding, positive regulation of protein ubiquitination, cell cycle arrest, metal ion binding, microtubule cytoskeleton, identical protein binding, cell cycle, Ras protein signal transduction, microtubule organizing center, microtubule, nucleus, response to DNA damage stimulus, signal transduction, zinc ion binding, negative regulation of cell cycle arrest, intracellular signal transduction
UniProt Accession Q5TZT2, Q9NS23, Q1W2K8, A8K9C3
Gene-Disease Assocation LUNG CANCER
Search EB-eye ENSG00000068028
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
MCF-7
2
E-GEOD-20081, E-GEOD-19639
HL-60
1
2
E-MTAB-37, E-GEOD-5258, E-GEOD-24147
NCIH2170
1
E-MTAB-37
U266B1
1
E-MTAB-37
cal 27
1
E-MTAB-62
292 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-19397, E-MEXP-66, E-GEOD-4219, ... (44 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-6740, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
primary T lymphocytes
1
E-GEOD-13909
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-MEXP-2280, E-MTAB-680, ... (49 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-MTAB-62, E-GEOD-2514, E-MTAB-37, E-MEXP-231
prostate carcinoma
2
E-GEOD-96, E-GEOD-5377
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-5550
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
FAB: M1 acute myeloid leukemia
1
E-GEOD-12662
hypernephroma
1
E-MTAB-62
157 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (24 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
placebo
2
E-MEXP-1335, E-MEXP-1327
U0126
1
E-GEOD-697
heregulin
1
E-GEOD-6462
mannitol
1
E-GEOD-6400
unknown
1
E-GEOD-7307
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-TABM-147, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-MEXP-1446, E-GEOD-22278, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-TABM-26, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-6802, E-GEOD-360

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-12198

Tumor grading
studied in E-GEOD-4290, E-TABM-147

Processing time: 0.448 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM